HPV Vaccine Program Drives Over 60% Drop in Cervical Cancer Deaths Among Vaccinated UK Cohorts

The UK introduced routine HPV vaccination for girls in 2008 using the bivalent Cervarix vaccine, achieving 80-85% coverage in school programs. Researchers linked NHS cancer registration and death records for cohorts born 1995-2000 against unvaccinated predecessors, controlling for screening participation. This produced the first mortality endpoint analysis rather than incidence proxies alone.

Earlier studies in The Lancet and JNCI documented 87% reduction in cervical cancer incidence and near-elimination of HPV16/18 infections in vaccinated groups, but mortality data lagged due to the decade-long progression from infection to death. The new figures close that gap while confirming transmission benefits in unvaccinated boys via herd effects.

Australia and Sweden report parallel incidence declines of 50-70% in high-uptake cohorts, yet few nations have mature mortality surveillance. The UK result underscores that school-based delivery plus catch-up campaigns outperform opportunistic models, a pattern missed in coverage focused solely on efficacy trials.

Sustained monitoring through 2035 will test durability against waning immunity and non-vaccine HPV types; current evidence supports extending gender-neutral programs to maintain elimination trajectories.